Contents
A Year of Structural Reform and Market Expansion Across Europe’s Cannabis Sector
The European cannabis industry has entered a new era of structural and regulatory transformation. Throughout 2024 and into 2025, the continent has witnessed landmark policy shifts, evolving commercial frameworks, and a surge in domestic and cross-border investment. As reform momentum accelerates, Europe’s cannabis market—spanning medical, adult-use, and CBD—is forecast to reach a total value of €XXX million in 2025, according to Prohibition Partners’ Market Sizing Forecasts (2025–2029).
Across the continent, governments are reassessing the role of cannabis within healthcare systems, criminal justice policy, and the broader economy. This year marks the first tangible movement towards harmonised regulation—though at varying speeds and scopes—among Europe’s leading markets.
Germany: Rapid Expansion Under New Medical Frameworks
Following the landmark reform enacted on 1 April 2024, Germany has experienced a dramatic restructuring of its medical cannabis ecosystem. Prescription access has expanded, insurance reimbursements have become more consistent, and domestic cultivation has scaled rapidly to meet demand. Simultaneously, cannabis cultivation associations—a cornerstone of Germany’s Pillar 1 adult-use model—have proliferated across federal states.
However, political uncertainty now clouds the rollout of the Pillar 2 commercial pilot programmes, originally designed to test regulated adult-use sales. The shift in power to the CDU/CSU coalition has introduced potential revisions to Germany’s roadmap, with new guidance expected later in 2025.
Switzerland: Data-Driven Legalisation Through Controlled Trials
Switzerland’s pioneering adult-use pilot programme continues to advance, with seven active trials underway across major cities including Zurich, Basel, and Bern. Preliminary indicators from these trials show promising outcomes in terms of safety, public health, and consumer behaviour.
In parallel, the Swiss National Council has approved a proposal to draft legislation enabling the controlled production and sale of adult-use cannabis at a national level. The preliminary draft law—currently in development—could make Switzerland the first European country to transition from pilot-based to full legalisation within a regulated framework.
Medical Production and Market Integration
Production capacity and export infrastructure are expanding across Europe’s medical cannabis heartlands. The Czech Republic, Denmark, Spain, Portugal, and North Macedonia have consolidated their roles as key cultivation and export hubs, while Germany and the United Kingdom are emerging as leaders in the manufacturing and processing of high-grade medical cannabis extracts.
After years of pilot schemes, Denmark and France are now taking concrete steps towards establishing permanent medical cannabis frameworks integrated into national healthcare systems. These reforms signal growing institutional acceptance of cannabis as a legitimate therapeutic option—and a pivotal step towards sustainable European market growth.
Outlook for 2025
The coming year will be defined by continued regulatory evolution and the maturation of Europe’s cannabis supply chain—from cultivation and processing to distribution and patient access. As commercial, clinical, and policy frameworks become more sophisticated, Europe is poised to emerge as a global hub for evidence-based cannabis innovation.
In the following articles, The European Cannabis Report: 2025 Edition will examine individual country markets in depth—highlighting the latest developments in medical and adult-use policy, investment trends, and market forecasts across Europe.
